Lorrey, S., Wachsmuth, L., Polania, J. W., Hoyt-Miggelbrink, A., Neff, C., Price, M., … Fecci, P. (2023). BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS. In NEURO-ONCOLOGY (Vol. 25).

Lorrey, Selena, Lucas Wachsmuth, Jessica Waibl Polania, Alexandra Hoyt-Miggelbrink, Corey Neff, Mackenzie Price, John Finlay, et al. “BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS.” In NEURO-ONCOLOGY, Vol. 25, 2023.

Lorrey S, Wachsmuth L, Polania JW, Hoyt-Miggelbrink A, Neff C, Price M, et al. BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS. In: NEURO-ONCOLOGY. 2023.

Lorrey, Selena, et al. “BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS.” NEURO-ONCOLOGY, vol. 25, 2023.

Lorrey S, Wachsmuth L, Polania JW, Hoyt-Miggelbrink A, Neff C, Price M, Finlay J, Cui X, Wilkinson D, Lerner E, Srinivasan E, Hotchkiss K, Ostrom Q, Fecci P. BETA-ADRENERGIC BLOCKADE LICENSES THE USE OF IMMUNOTHERAPY IN PRIMARY AND METASTATIC BRAIN TUMORS. NEURO-ONCOLOGY. 2023.